LEXICON PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 0 shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Notes › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2022-03-10
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2021-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2020-09-30 was 51.00K shares, a 1600.00% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2019-09-30 was 3.00K shares.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2018-09-30 was 0.00 shares.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2021 was 0.00 shares.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2020 was 0.00 shares, a 100.00% decline from fiscal 2019.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2019 was 164.00K shares.
- LEXICON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2018 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month |
|---|---|---|---|
| 2021-12-31 | 0.00 shares 10-K · filed 2022-03-10 | ||
| 2021-09-30 | 0.00 shares 10-Q · filed 2021-11-09 | 0.00 shares 10-Q · filed 2021-11-09 | |
| 2020-12-31 | 0.00 shares 10-K · filed 2022-03-10 | ||
| 2020-09-30 | 51.00K shares 10-Q · filed 2021-11-09 | 0.00 shares 10-Q · filed 2021-11-09 | |
| 2019-12-31 | 164.00K shares 10-K · filed 2022-03-10 | ||
| 2019-09-30 | 3.00K shares 10-Q · filed 2020-10-30 | 177.00K shares 10-Q · filed 2020-10-30 | |
| 2018-12-31 | 0.00 shares 10-K · filed 2021-03-12 | ||
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-07 | 0.00 shares 10-Q · filed 2019-11-07 | |
| 2017-12-31 | 0.00 shares 10-K · filed 2020-03-12 | ||
| 2015-12-31 | 1.78M shares 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |